F Malgo1, N A T Hamdy1, T J Rabelink2, H M Kroon3, K M J A Claessen4, A M Pereira4, N R Biermasz4, N M Appelman-Dijkstra1. 1. Centre for Bone Quality, Division Endocrinology. 2. Centre for Bone Quality, Division Nephrology. 3. Centre for Bone Quality, Department of Radiology. 4. Centre for Bone QualityCentre for Endocrine Tumours Leiden, Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
OBJECTIVE: Acromegaly is a rare disease caused by excess growth hormone (GH) production by the pituitary adenoma. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of relatively normal bone mineral density (BMD). We aimed to evaluate tissue-level properties of bone using impact microindentation (IMI) in well-controlled patients with acromegaly aged ≥18 years compared to 44 controls from the outpatient clinic of the Centre for Bone Quality. DESIGN AND METHODS: In this cross-sectional study, bone material strength index (BMSi) was measured in 48 acromegaly patients and 44 controls with impact microindentation using the osteoprobe. RESULTS: Mean age of acromegaly patients (54% male) was 60.2 years (range 37.9-76.5), and 60.5 years (range 39.8-78.6) in controls (50% male). Patients with acromegaly and control patients had comparable BMI (28.2 kg/m2 ± 4.7 vs 26.6 kg/m2 ± 4.3, P = 0.087) and comparable BMD at the lumbar spine (1.04 g/cm2 ± 0.21 vs 1.03 g/cm2 ± 0.13, P = 0.850) and at the femoral neck (0.84 g/cm2 ± 0.16 vs 0.80 g/cm2 ± 0.09, P = 0.246). BMSi was significantly lower in acromegaly patients than that in controls (79.4 ± 0.7 vs 83.2 ± 0.7; P < 0.001). CONCLUSION: Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels. Our findings also suggest that methods other than DXA should be considered to evaluate bone fragility in patients with acromegaly.
OBJECTIVE:Acromegaly is a rare disease caused by excess growth hormone (GH) production by the pituitary adenoma. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of relatively normal bone mineral density (BMD). We aimed to evaluate tissue-level properties of bone using impact microindentation (IMI) in well-controlled patients with acromegaly aged ≥18 years compared to 44 controls from the outpatient clinic of the Centre for Bone Quality. DESIGN AND METHODS: In this cross-sectional study, bone material strength index (BMSi) was measured in 48 acromegalypatients and 44 controls with impact microindentation using the osteoprobe. RESULTS: Mean age of acromegalypatients (54% male) was 60.2 years (range 37.9-76.5), and 60.5 years (range 39.8-78.6) in controls (50% male). Patients with acromegaly and control patients had comparable BMI (28.2 kg/m2 ± 4.7 vs 26.6 kg/m2 ± 4.3, P = 0.087) and comparable BMD at the lumbar spine (1.04 g/cm2 ± 0.21 vs 1.03 g/cm2 ± 0.13, P = 0.850) and at the femoral neck (0.84 g/cm2 ± 0.16 vs 0.80 g/cm2 ± 0.09, P = 0.246). BMSi was significantly lower in acromegalypatients than that in controls (79.4 ± 0.7 vs 83.2 ± 0.7; P < 0.001). CONCLUSION: Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels. Our findings also suggest that methods other than DXA should be considered to evaluate bone fragility in patients with acromegaly.
Authors: E Vitali; E Palagano; M L Schiavone; G Mantovani; C Sobacchi; G Mazziotti; A Lania Journal: J Endocrinol Invest Date: 2022-01-12 Impact factor: 4.256
Authors: M Schoeb; F Malgo; J J M Peeters; E M Winter; S E Papapoulos; N M Appelman-Dijkstra Journal: Osteoporos Int Date: 2020-04-08 Impact factor: 4.507
Authors: Pamela Rufus-Membere; Kara L Holloway-Kew; Adolfo Diez-Perez; Mark A Kotowicz; Julie A Pasco Journal: BMJ Open Date: 2018-12-22 Impact factor: 2.692
Authors: Luis Gracia-Marco; Sheila Gonzalez-Salvatierra; Antonia Garcia-Martin; Esther Ubago-Guisado; Beatriz Garcia-Fontana; José Juan Gil-Cosano; Manuel Muñoz-Torres Journal: J Clin Med Date: 2021-02-09 Impact factor: 4.241
Authors: Kim M J A Claessen; Iris C M Pelsma; Herman M Kroon; Antoon H van Lierop; Alberto M Pereira; Nienke R Biermasz; Natasha M Appelman-Dijkstra Journal: Endocrine Date: 2021-08-26 Impact factor: 3.633
Authors: M Schoeb; E M Winter; F Malgo; I B Schipper; R J P van der Wal; S E Papapoulos; N M Appelman-Dijkstra Journal: Osteoporos Int Date: 2022-03-21 Impact factor: 5.071
Authors: Manuela Schoeb; Neveen A T Hamdy; Frank Malgo; Elizabeth M Winter; Natasha M Appelman-Dijkstra Journal: Front Endocrinol (Lausanne) Date: 2020-02-07 Impact factor: 5.555